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Introduction
We have recently identified a novel cancer-testis antigen, lymphocyte antigen 6 complex locus K (LY6K, synonymous with URLC10), frequently overexpressed in lung cancer, head and neck malignant tumor (HNMT), esophageal carcinomas, bladder cancer, gastric cancer, and various other malignancies. 1 Previous studies have reported that LY6K 177-186 -A24 short peptide (SP) stimulated cytotoxic lymphocytes (CTLs) killed esophageal cancer cells expressing endogenous LY6K antigen. 2 Furthermore, LY6K 177-186 -A24 SP-specific CTLs have been detected among tumor-infiltrating lymphocytes, regional lymph node-associated lymphocytes, and PBMCs obtained from HLA-A24 (A*24:02)-positive patients with esophageal cancer 3 . Phase I/II clinical trials of LY6K 177-186 -A24 SP immunotherapy for treatment of lung, gastric, and esophageal cancers has yielded promising results and Phase I/II clinical trials assessing LY6K 177-186 -A24 SP vaccines for patients with HNMTs are currently underway. [4] [5] [6] [7] [8] In these trials, we observed that vaccination with LY6K 177-186 -A24 SP induced antigen-specific CTL responses and improved progression-free survival among patients with advanced esophageal cancer. 6 Thus, further investigation is warranted to test the premise that LY6K is an attractive target molecule for cancer immunotherapy.
Th cells are necessary elements of cellular immunity, priming tumor-specific CTLs and influencing the differentiation and expansion of tumor antigen specific CTLs essential for generating and maintaining long-lasting CTL responses. 9,10 T helper type 1 (Th1) cells have a direct role in tumor elimination and interferon-γ (IFNγ) secreted by Th1 cells mediates anti-angiogenic effects. Furthermore, Th1 cells pave the way for entry of CTLs at the tumor site. 11 Tumor-specifc Th1 cells also control tumor development and progression via the activation of dendritic cells (DCs), natural killer (NK) cells, and type 1 macrophages. 9 Vaccination-induced tumor-specific Th cells with tumor homing capabilities can deliver inflammatory cytokines such as IFNγ to the local tumor microenvironment. Finally, antigen-specific Th cells can enhance and sustain tumor-specific immunity over time. Therefore, the identification of peptides that can activate both tumor-specific Th1 cells as well as CTLs is important for induction of effective antitumor immunity in tumor-bearing hosts.
DCs are capable of processing exogenous antigens and activating tumor-specific CTL responses via cross-presentation. Melief et al. reported a synthetic long peptide (LP) vaccine encompassing a CTL epitope and possessing immunotherapeutic potential. Specifically, LP-vaccine treated patients' DCs take up the peptide, process it, and present all possible CTL epitopes and Th cell epitopes in the context of various HLA class I and class II molecules. 12, 13 Disis et al. reported that vaccination with a CTL-epitope LP derived from human epidermal growth factor receptor 2 (EGFR2, better known as HER2) generated robust and persistent tumor-specific T-cell immunity in patients with metastatic breast cancer. 14 Recent clinical studies using a telomerase-derived LP encompassing CTL-epitopes (GV1001) increased the survival of cancer patients in combination with radio-and chemotherapy. 15 Thus, we proposed that an ideal peptide vaccine for cancer immunotherapy may be optimally composed of a single polypeptide spanning epitopes for both Th cells and CTLs. 12, [16] [17] [18] In this study, we sought to identify a LY6K-derived LP with the potential to induce immunologic activity in both Th1 cells and CTLs to further develop peptide-based vaccine immunotherapy. We found that LY6K 172-191 -LP successfully triggered Th1-cell responses in individuals expressing several common HLA allelic variants, including HLA-DR, -DP or -DQ alleles, and that efficient cross-presentation of the LY6K 172-191 -LP induced LY6K 177-186 -A24 SP-specific CTLs. In addition, we also observed LY6K 172-191 -LP enhanced induction of LY6K 177-186 -A24 SP-specific CTLs in PBMCs from healthy donors and HNMT patients.
Results

Identification of immunogenic LY6K-derived LPs encompassing helper T cell epitopes
To identify LPs comprising candidate HLA-class II binding Th cell epitopes of LY6K, we first examined the amino acid sequence of LY6K using a recently developed immune epitope database (IEDB) computer algorithm previously described. 19, 20 We focused on the protein regions with multiple Th cell epitope prospects ( Fig. S1A ; Table S1 ). An LY6K 172-191 -LP predicted by IEDB to be a potent HLA class II-binding peptide, was identified proximal to a known 10-mer CTL-epitope, LY6K 177-186 -A24 SP that is recognized by HLA-A24-restricted CTLs (Fig. S1B) . Another peptide, LY6K 119-142 -LP, was also predicted to be a potent HLA class II-binding peptide, although it did not include a known CTL-epitope sequence. Therefore, 2 candidate LPs, LY6K 119-142 -LP and LY6K 172-191 -LP, both of which were predicted to have a strong binding affinity for HLA-class II molecules (e.g., HLA-DP5, -DR8, -DR9, or -DR15), were synthesized for subsequent analyses.
Purified CD4 + T cells were obtained from the PBMCs of 4 healthy donors by positive selection with magnetic microbeads. These CD4 + T cells were stimulated at weekly intervals with autologous DCs or PBMCs pulsed with either LY6K 119-142 -LP or LY6K 172-191 -LP, as described in Materials and Methods. After at least 3 rounds of stimulation, the LY6K-LP-specific immunologic responses of the corresponding cultured CD4 + T cells were examined by IFNγ ELISPOT assays. The Th cells generated from HLA-DP5 + HD1 produced a significant amount of IFNγ in response to LY6K 119-142 -LP-pulsed PBMCs in an HLA-DP-dependent manner ( Fig. 1, left panel) . The bulk Th cells also specifically recognized HLA-DP5-expressing L cells (L-DP5) pulsed with LY6K 119-142 -LP in an HLA-DP-dependent manner, but not irrelevant peptide (EBNA)-pulsed L-DP5 cells or LY6K 119-142 -LP-pulsed HLA-DR4-expressing L cells (L-DR4; Fig. 1A , right panel). These results indicated that LY6K 119-142 -LP was specifically presented by HLA-DP5. To investigate whether LY6K 119-142 -LP induces responses in Th cells restricted by other HLA class II molecules, CD4 + T-cells from DR8 + and DR15 + healthy donors (HD2 and HD3) were also tested. We confirmed that LY6K 119-142 -LP also stimulates HLA-DR8-restricted Th cells and HLA-DR15-restricted Th cells ( Fig. 1B and C; Fig. S1C ). Thus, LY6K 119-142 -LP binds to HLA-DP5, HLA-DR8, and HLA-DR15, suggesting that LY6K 119-142 -LP encompasses several Th cell epitopes presented by high frequency HLA class II molecules. 21, 22 Next, we assessed whether LY6K 172-191 -LP, a peptide spanning a known CTL-epitope, could also generate active Th cells. The Th cells originating from 2 HLA-DR15 + donors (HD2 and HD3) produced a significant amount of IFNγ in response to LY6K 172-191 -LP-pulsed PBMCs in an HLA-DR-dependent manner. The bulk Th cells specifically recognized HLA-DR15 expressing L cells (L-DR15) pulsed with LY6K 172-191 -LP in an HLA-DR-dependent manner ( Fig. 1D and E) . CD4 + T-cells from an HLA-DR15-negative donor (HD4) were tested to investigate whether LY6K 172-191 -LP can induce Th cells restricted by other HLA class II molecules. LY6K 172-191 -LP could stimulate HLA-DQ-restricted bulk Th cells originating from this donor ( Fig. 1F) . Indeed, LY6K 172-191 -LP robustly generated Th cells expressing IFNγ, suggesting that LY6K 172-191 -LP also encompasses several Th cell epitopes. In these healthy donors, LY6K 177-186 -A24 SP control failed to stimulate LY6K 172-191 -LP-specific Th cells ( Fig. 1D-F) . Taken together, LY6K-LPs stimulation induced IFNγ-producing Th cells derived from 4 healthy donors.
LY6K-LPs encompass naturally processed helper T cell epitopes
We proceeded to assess whether DCs take up and process the LY6K protein to stimulate LY6K-LP specific Th cells. Autologous DCs loaded with recombinant LY6K protein were prepared and used as antigen-presenting cells (APCs) in IFNγ ELISPOT assays. 23,24 HLA-DP5-restricted LY6K 119-142 -LP-reactive bulk Th cells efficiently recognized DCs loaded with LY6K protein in an HLA-DP-dependent manner, but did not recognize control protein-loaded DCs, indicating that LY6K 119-142 -LP encompasses an epitope naturally processed and presented by HLA-DP5 molecules ( Fig. 2A) . HLA-DR15-and HLA-DQ-restricted LY6K 172-191 -LP-specific Th-clones also recognized autologous DC loaded with LY6K protein, indicating that LY6K 172-191 -LP similarly constitute epitopes naturally processed and presented by HLA-DR15 and HLA-DQ molecules (Fig. 2B) .
LY6K-LPs stimulate Th1-type CD4 + T cells
In order to further characterize LY6K-LP-reactive Th cells, we next applied the Bio-Plex system to measure the levels of several cytokines released from epitope-specific Th cells in response to stimulation by the cognate peptide. LY6K 119-142 -LP-specific bulk Th cells from HD1 and HD3 stimulated with cognate peptide specifically produced IFNγ, tumor-necrosis factor-α (TNF-α), interleukin-2 (IL-2), colony stimulating factor 2 (CSF2, commonly known as GM-CSF), and chemokine ligand 4 (CCL4, better known as MIP-1β), indicating Th1 polarized secretory characteristics ( Fig. S2A , upper panels and data not shown). LY6K 172-191 -LP-specific Th-clone from HD4 produced a large amount of these cytokines after stimulation, suggesting LY6K 172-
191
-LP can potently induce multifunctional Th1 cells ( Fig. S2A , lower panels). Similar results were obtained from LY6K 172-191 -LP-specific Th cells established from HD3 (data not shown). The lysosomal-associated membrane protein 1a (LAMP1a, also known as CD107a) was detected on the LY6K 119-142 -LP-specific bulk Th1 cells (HD1, HD2 and HD3) and LY6K 172-191 -LP-specific bulk Th1 cells (HD2, HD3, and HD4) stimulated with cognate peptides ( Fig. S2B and data not shown), as has been previously demonstrated for antiviral CD4 + effectors and tumor-infiltrating lymphocytes. [25] [26] [27] [28] Presence of LY6K-specific Th1 cells in HNMT patients before and after vaccination with LY6K 177-186 -A24 SP We next assessed LY6K-LPs-specific Th1 cell responses in the peripheral blood of 23 HNMT patients enrolled in 2 CTL-epitope peptide-vaccine trials. LY6K-reactive Th1 cells were derived from patients pre-and post-LY6K 177-186 -A24 SP vaccination and characterized by their production of IFNγ upon stimulation with LY6K-LP variants in vitro. 9 The donor clinical characteristics and T-cell responses are summarized in Table 1 . After 1 wk of stimulating patient-derived PBMCs with LY6K-LPs in vitro, the frequency of individual LY6K-LP-specifc Th1 cells among blood lymphocytes was detected by IFNγ ELISPOT assay (Fig. 3A) . PBMCs from 9 healthy donors were used as control. Responses were considered positive when the number of IFNγ-secreting cells was at least 2-fold above the negative control. LY6K-specific Th1 cell responses were observed in LY6K 177-186 -A24 SP vaccinated HNMT patients. As summarized in Table 1 , specifically, 10 of 23 (44%) of patients were reactive to LY6K 119-142 -LP, and 16 of 23 (70%) of patients responded to LY6K 172-191 -LP but no specific immune responses to LY6K-LPs were detected among the 9 healthy donors ( Fig. S3A ; Table 1 ). We also found that the number of specific IFNγ-spots per 10 5 CTL-epitope vaccinated patient-derived PBMCs immunoreactive against LY6K 119-142 -LP and LY6K 172-191 -LP were significantly larger than in PBMCs from healthy donors ( Fig. 3B ; P < 0.001). Although the increase of LY6K 119-142 -LP-specific spots from vaccinated patient PBMCs was not significant compared with those derived from HNMT patients before vaccination, the mean number of LY6K 172-191 -LPspecific IFNγ spots in vaccinated patient PBMCs was significantly larger than that of HNMT patients before vaccination ( Fig. 3B : P < 0.05). The proportion of donors responding to LY6K 172-191 -LP in HNMT patients after vaccination was also significantly higher than in HNMT patients before vaccination (P < 0.05; Fig. 3C;  Fig. S3B ). Interestingly, specific responses to LY6K-LPs were elicited or augmented by repeated vaccinations (Fig. S3C) . In comparing the numbers of LY6K-LP-specific IFNγ spots in vaccinated HNMT patients with advanced cancer (CTR-8379, n = 13) and vaccinated HNMT patients receiving postoperative adjuvant immunotherapy (CTR-8380, n = 7), the number of LY6K-LPspecific IFNγ spots in those patients receiving postoperative adjuvant immunotherapy was significantly higher than in vaccinated HNMT patients with advanced cancer (Fig. S3D) . In assessments of HLA-subtype restriction, LY6K-LP-specific IFNγ production by Th1 cells derived from 7 HNMT patients was significantly inhibited by addition of the anti-HLA-Class II mAbs, but not by the anti-HLA-Class I mAb ( Fig. 3D) . HLA-Class II alleles of LY6K 119-142 -LP-specific HLA-DR-restricted Th1 cells derived from 2 HNMT patients were negative for HLA-DR8 and -DR15 ( Fig. 3D ; LY6K 119-142 -LP; HNMT31 and 107). HLA-Class II alleles of LY6K 172-191 -LP-specific HLA-DR-restricted Th1 cells in 5 HNMT patients were negative for HLA-DR15 ( Fig. 3D ; LY6K 172-191 -LP; HNMT31, 41, 42, 107, and 108). These results suggest that LY6K 119-142 -LP and LY6K 172-191 -LP can be recognized by Th1 cells restricted by other HLA-Class II molecules not previously identified by the in vitro experiments assaying lymphocytes from healthy donors. Taken together, these observations suggest that HNMT patients are able to mount LY6K-specific Th1 cell responses and IFNγ production by LY6K 177-186 -A24 SP-specific CTLs was measured by intracellular labeling. Fixed DCs, unable to cross present but able to present LY6K 177-186 -A24 SP as efficiently as live DCs (Fig. 4A) , were used to exclude or evaluate the contribution of exogenous presentation of LP degradation products in the T-cell response. LY6K 172-191 -LP induced a significant proportion of IFNγ secreting tetramer + (i.e., HLA-A24 (A*24:02)/LY6K 177-186 ) CD8 + T-cells only when they when immunogens were cross presented by unfixed DCs (DC + LP). LY6K 172-191 -LP-pulsed fixed DCs could not stimulate LY6K 177-186 -A24 SP-specific CTLs, similar to control LP-pulsed unfixed DCs (Fixed DC + LP and DC + control LP).
We next investigated whether LY6K 172-191 -LP-pulsed autologous DCs could induce expansion of LY6K 177-186 -A24 SP-specific CTLs. LY6K 177-186 -A24 SP-specific bulk CTLs generated from ex vivo SP-stimulated purified CD8 + T cells derived from HLA-A24 + HD3 were restimulated with LY6K 172-191 -LP-pulsed autologous DCs. As shown in Figure 4B , the population of HLA-A24/ LY6K 177-186 -specific tetramer + CD8 + cells was expanded by stimulation with LY6K 172-191 -LP-pulsed DCs on day 7, but decreased when the LY6K 177-186 -A24 SP-specific bulk CTLs were stimulated with control-LP-pulsed DCs. These results suggest that the expansion of LY6K 177-186 -A24 SP-specific CTLs was induced by DC cross-presentation of LY6K 172-191 -LP.
LY6K 172-191 -LP induce efficient expansion of LY6K 177-186 -A24
SP-specific CTLs derived from vaccinated HNMT patients
We next assessed whether LY6K 172-191 -LP could induce in vitro expansion of LY6K 177-186 -A24 SP-specific CTLs among PBMCs obtained from 5 HNMT patients vaccinated with LY6K 177-186 -A24 SP. HNMT patient PBMCs were cultured with 10 μg/mL LY6K 172-
191
-LP to which 20 IU/mL IL-2 and 5 ng/mL IL-7 were added on days 0 and 2. On days 0 (ex vivo) and 7, PBMCs were stained with a HLA-A24/LY6K 177-186 -specific tetramer. As shown in Figure 4C , when PBMCs isolated from HNMT108 were stained with a HLA-A24/LY6K 177-186 -specific tetramer before in vitro culture (ex vivo), the frequency of tetramer + cells was only 0.05% of CD8 + T-cells. The tetramer + cells were markedly expanded by 1-wk in vitro stimulation of PBMCs with LY6K 172-191 -LP (without adding LY6K 177-186 -A24 SP) with the frequency of LY6K 177-186 -A24 SP-specific CTLs increasing to 0.35% of CD8 + T-cells. LY6K-specific IFN-γ production by CTLs was also assayed upon stimulation with LY6K 177-186 -A24 SP on day 7 (Fig. 4C, bar graph) . The increase in the proportion of tetramer + CD8 + cells was more than 2-fold that of control peptide treated cells in 4 of 5 HNMT patients ( Fig. 4D; HNMT43, 105, 108, and 110) . These results suggest that LY6K 177-186 -A24 SP-specific CTLs might be augmented by DC cross-presentation of LY6K 172-191 -LP without direct stimulation by LY6K 177-186 -A24 SP in HNMT patients. Similar results were obtained from 9 of 11 HNMT patients vaccinated with LY6K 177-186 -A24 SP when the PBMCs were cultured with a mixture of LY6K 119-142 -LP and LY6K 172-191 -LP ( Fig. S4A and B) . Interestingly, HLA-A24/LY6K 177-186 -specific tetramer + cells detected in the peripheral blood of HNMT42 before LY6K 177-186 -A24 SP vaccination were also significantly expanded by stimulation with a mixture of LY6K 119-142 -LP and LY6K 172-191 -LP ( Fig. S4C) .
Cross-presentation of LY6K 172-191 -LP efficiently primes LY6K-specific CD8 + T cells in vitro and in vivo
Subsequently, we examined the capacity of LY6K 172-191 -LP to prime naïve LY6K 177-186 -A24 SP-specific human CTLs by tetramer labeling. HLA-A24-restricted LY6K 177-186 -A24 SP-specific CTLs were significantly induced by culturing PBMCs from 3 HLA-A24 + healthy donors (HD1, HD3, HD4) with LY6K 172-191 -LP for 2 wk (Fig. 4E and data not shown) .
Next, humanized transgenic mice expressing HLA-A24 were immunized 3 times with LY6K 172-191 -LP. The capacity of LY6K 172-
191
-LP to prime LY6K 177-186 -A24 SP-specific murine CTLs was then examined by an ex vivo IFNγ ELISPOT assay. The CD8 + T-cells isolated from LY6K 172-191 -LP-vaccinated HLA-A24 mice produced IFNγ in response to stimulation with bone marrow-derived DCs pulsed with the LY6K 177-186 -A24 SP (Fig. 4F) . These results demonstrate that following uptake LY6K 172-191 -LP, APCs can crossprime LY6K 177-186 -A24 SP-specific CTLs in vitro and in vivo.
Enhanced induction of LY6K 177-186 -A24 SP-specific CTLs by LY6K-LP-specific Th cells
We next sought to investigate whether LY6K-LP stimulated Th cells could enhance induction of LY6K 177-186 -A24 SP-specific CTLs. LY6K-LP-specific bulk CD4 + T cells and LY6K 177-186 -A24 SP-specific bulk CD8 + T cells derived from HD3 were co-cultured with autologous DCs in the presence of LY6K 177-186 -A24 SP, LY6K 177-186 -A24 SP + control LP, or LY6K 177-186 -A24 SP + LY6K-LP. After 1-wk in vitro culture with peptides, the cells were stained with HLA-A24/LY6K 177-186 -specific tetramer. As shown in Figure 5A , the addition of LY6K 177-186 -A24 SP + LY6K 119-142 -LP or LY6K 177-186 -A24 SP + LY6K 172-191 -LP significantly increased the absolute number of LY6K 177-186 -A24 SP-specific CD8 + T cells compared with the addition of LY6K 177-186 -A24 SP alone or LY6K 177-186 -A24 SP + control LP. We also observed that the activated Table 1 , hnMT43, 105, 108, and 110) with similar results achieved. (D) The increases (fold increase) in proportion of (Continued on following page) LY6K 172-191 -LP-specific Th cells enhanced induction of HLA-A24/ LY6K 177-186 -specific tetramer + T cells derived from HLA-A24 + HD4 (data not shown).
Next, we assessed the synergistic effect of LY6K-LP on induction of LY6K 177-186 -A24 SP-specific CTLs among PBMCs from HNMT patients (HNMT31, 42, and 43). PBMCs collected from HNMT43 2 mo after immunization were cultured for 7 d with LY6K 177-186 -A24 SP alone, LY6K 177-186 -A24 SP + control LP, LY6K 177-186 -A24 SP + LY6K 119-142 -LP, or LY6K 177-186 -A24 SP + LY6K 172-191 -LP. After 1-wk in vitro culture with peptides, the cells were stained with HLA-A24/LY6K 177-186 -specific tetramer. As shown in Figure 5B and C, when the patient-derived PBMCs were cultured with LY6K 177-186 -A24 SP + LY6K 172-191 -LP, the absolute number of LY6K 177-186 -A24 SP-specific CD8 + T cells was significantly increased in comparison with those cultured with LY6K 177-186 -A24 SP alone or LY6K 177-186 -A24 SP + control LP. On the contrary, there was no synergistic effect of LY6K 119-142 -LP on induction of LY6K 177-186 -A24 SP-specific CTLs obtained from HNMT43 (Fig. 5C) . Similar results were obtained when patient CTLs were assessed at 1 mo after immunization (data not shown). This result was reproducible in that similar results were obtained using CTLs derived from HNMT31 and HNMT42 showing that either LY6K 119-142 -LP or LY6K 172-191 -LP could enhance CTL responses to LY6K 177-186 -A24 SP (Fig. S5) . These results suggest that LY6K-LPs can synergistically induce LY6K 177-186 -A24 SP-specific CTLs.
Discussion
We identified 2 LY6K-LPs, specifically LY6K 119-142 -LP and LY6K 172-191 -LP, constituting Th epitopes. A known CTL-epitope, LY6K 177-186 -A24 SP was embedded within LY6K 172-191 -LP. Although not shown, we did test 2 other LY6K-LPs, LY6K 58-72 -LP and LY6K 206-223 -LP, that were predicted to have strong binding affinity to multiple HLA-class II molecules. However, we could not induce LP-specific Th cells in peripheral blood obtained from healthy donors.
In this study, we determined that LY6K 177-186 -A24 SP-specific CTLs can be induced by cross-presentation of LY6K 172-191 -LP in vitro and in vivo. We also demonstrated the presence of LY6K-LPs-specific Th1 responses HNMT patients, whereas there was no response among PBMCs derived from healthy donors after 1-wk in vitro stimulation with LY6K-LPs. This is the first report of the presence of LY6K-specific Th responses in patients with HNMT.
Recent studies evaluated the CTL repertoire of melanoma patients exhibiting complete regression of cutaneous metastases after melanoma antigen A3 (MAGE-A3) vaccination with canary pox viral vector combined with peptide. [29] [30] [31] After immunization, a new wave of antigen-specific CTL clones arose in the peripheral blood, providing solid evidence that the phenomenon of epitope spreading is critical to the development of effective anticancer immunity elicited by peptide vaccines. These results further implicate functional interactions between vaccine-induced CTLs and malignant cells that facilitate the induction of large numbers of tumor-specific CTLs, cytocidal effector immune cells that subsequently proceed to destroy tumor cells. Interestingly, the frequency of LY6K 172-191 -LP-specific Th cell responses and the number of IFNγ-producing LY6K 172-191 -LP-specific Th1 cells in HNMT patients after CTL-epitope vaccination were significantly larger than those detected in patients prior to vaccination. LY6K-LPsspecific responses in some HNMT patients were augmented or elicited by repeated LY6K 177-186 -A24 SP vaccination. We speculate that LY6K-LP-specific Th responses occurring in LY6K 177-186 -A24 SP vaccinated HNMT patients may be a phenomenon of intramolecular epitope spreading triggered by CTL-epitope vaccination.
Disis et al. reported that vaccination with a herceptin-2 (HER-2/ neu)-derived LP encompassing an HLA-A2-restricted CTLepitope elicited the embedded CTL-epitope specific CD8 + T cells in cancer patients. 14 They showed that tumor-specific CTLs can be elicited in vivo via cross-presentation of HER-2/neu-derived LP. Such T-cell responses are considered to be crucial for tumor eradication and generating long-term memory. 32 With this premise in mind, we identified an immunogenic LY6K 172-191 -LP that encompasses both Th epitopes and CTL-epitope and demonstrated that cross-presentation of LY6K 172-191 -LP induced priming and expansion of LY6K-specific CTLs in vitro and in vivo. Nevertheless, it remains possible that LY6K 177-186 -A24 SP was produced from degradation of LY6K 172-191 -LP and the degraded product may subsequently stimulate LY6K-specific CTLs. Vaccination with LY6K 172-191 -LP may, therefore, potentially elicit combined Th and CTL responses. A recent clinical trial showed that targeting Th cells with DCs pulsed with both HLA class I and II-restricted epitopes effectively enhanced vaccine-specific immune responses and improved clinical outcome. 33 LY6K-LPs bolstered the induction of LY6K 177-186 -A24 SP-specific CTLs derived from both healthy donors and HNMT patients in vitro. Thus, LY6K-LPs administered in combination with LY6K 177-186 -A24 SP immunotherapy may be able to augment the elicitation of antigen-specific CTLs. The checkpoint blockade induced by specific immunoregulatory antibodies such as those targeting cytotoxic T lymphocyte associated protein-4 (CTLA-4), programmed cell death 1 (PD-1), or its ligand PD-L1, applied in combination with therapeutic vaccines have been previously illustrated to act synergistically. 34 The checkpoint blockade may be a good candidate for future combinatorial therapy with LY6K-derived LPs vaccine. Based on the HLA-subtypes found to be capable of antigen presentation from studies using healthy donors, LY6K 119-142 -LP and LY6K 172-191 -LP are predicted to be useful in approximately 82% of the total population. 21, 22 We showed that LY6K 119-142 -LP induced HLA-DP5, HLA-DR8, or HLA-DR15-restricted Th cells in healthy donors and also induced HLA-DR or HLA-DQ-restricted Th cells in 3 HNMT patients (HNMT31, 41, and 107). However, these HNMT patients were negative for HLA-DP5, -DR8, or -DR15 alleles. We also showed that LY6K 172-191 -LP induced HLA-DR15 or HLA-DQ-restricted Th cells in healthy donors. Although we observed that the presence of HLA-DR-restricted LY6K 172-191 -LPspecific Th cells in 7 HNMT patients, HLA-Class II alleles of 5 HNMT patients (HNMT31, 41, 42, 107, and 108) were negative for HLA-DR15. These results suggest that LY6K-LPs may encompass Th cell epitopes not previously identified in experiments in vitro involving cells derived from healthy donors and LY6K-LPs may be broadly useful in the majority of patients.
In this study, 44% and 70% of HNMT patients demonstrated immunity to LY6K 119-142 -LP and LY6K 172-191 -LP respectively, and these are significantly higher than the proportion of healthy donors responding to LY6K-LPs. Weide et al. reported that the presence of circulating Th cells responding to melanoma antigens Melan-A or NY-ESO-1 has a strong independent prognostic impact on survival among chemotherapy-treated advanced melanoma patients. 35 Another study has shown a possible synergy between the telomerase-specific Th response with chemotherapy in lung cancer. 36 The introduction of immunotherapy in clinical practice also emphasized the influence of immune responses on cancer prognosis and chemotherapy effectiveness. 15, 37, 38 These pieces of evidence support the hypothesis that induction or augmentation of LY6K-specific Th1 cells by vaccination with LY6K-LPs may improve the clinical outcome of cancer patients when combined with chemotherapy or other standard therapies. 39, 40 LY6K-LPs-specific Th responses in HNMT patients may, therefore, be predicted to positively influence overall survival. The impact of LY6K-specific Th responses on clinical outcome will be evaluated in future studies.
In conclusion, LY6K-LPs provide a useful tool for propagation of both LY6K-specific Th1 cells and CTLs, and may synergize with CTL-epitopes to effect cancer cell killing. These findings provide rationale for a clinical trial of LY6K-LP-based immunotherapy against a broad spectrum of cancer types.
Materials and Methods
LY6K-epitope immunotherapy clinical trial HNMT patients
Blood samples were collected from 23 patients with HNMTs enrolled in 2 CTL-epitope vaccine trials. The immune responses of Th cells reactive to LY6K-LPs were investigated. These Phase I/II clinical trials of cancer immunotherapy using 3 HLA-A24-binding short peptides (SPs), (clinical grade peptides 9-10 amino acids in length) derived from 3 cancer-testis antigens, LY6K (LY6K 177-186 -A24), IMP-3 (IMP-3 508-516 -A24), and CDCA1 (CDCA1 56-64 -A24) were reviewed and approved by the Institutional Review Board of Kumamoto University, Japan. 2, 18 Peptides were emulsified in 500 µL Montanide ISA51 and injected subcutaneously (s.c.) on days 0, 7, 14, 28, 42, 56, 63, and 70, then monthly until tumor progression or toxicity were observed. The immunization protocol using LY6K, IMP-3, and CDCA1-derived SPs (1 mg each) was determined on the basis of other peptide-vaccine clinical trials using these SPs. 4,6 Toxicities caused by the vaccination therapy were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3. All patients with HNMTs were selected on the basis of HLA-A24 presence after providing written informed consent and according to the Helsinki Accord. The patients suffered from inoperable advanced HNMT with recurrent or metastatic tumors that were resistant to standard therapy. Patients were enrolled in the trial under the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) number 000008379 (CTR-8379). HNMT patients with radical resection were enrolled in the trial under UMIN-CTR number 000008380 (CTR-8380). In the latter trial, HNMT patients were treated with postoperative peptide vaccine combined with S-1, ifosfamide, or doxorubicin. As of the date of manuscript submission, these clinical trials and analyses remained ongoing.
Genetically engineered antigen-presenting cell lines Mouse fibroblast cell lines (L-cells), genetically engineered to express the HLA class II heterodimeric pairs DR4 (DRB1*04:05) and L-DR4, DR8 (DRB1*08:03) and L-DR8, DR15 (DRB1*15:02) and L-DR15, or DP5 (DPB1*05:01) and L-DP5, were used as antigen-presenting cells (APCs).
Prediction of HLA Class II-binding peptides
To predict possible promiscuous HLA class II-binding human LY6K-derived peptides, the amino acid sequence of the human LY6K protein was analyzed by the immune epitope database (IEBD) recommended method, http://tools.immuneepitope.org/ analyze/html/mhc_II_binding.html. 19, 20 The program analyzed 15 amino-acid-long sequences offset to encompass the entire protein. We defined the score of percentile rank less than 10 as indication of stronger binding affinity to HLA class II molecules and selected the regions predicted to have high binding affinity to at least 2 frequently observed HLA class II molecules. The 24-mer LP, LY6K 119-142 -LP (KWTEPYCVIAAVKIFPRFFMVAKQ) was predicted to have a strong binding affinity to multiple HLA class II molecules encoded by DPB1*05:01, DRB1*08:03, DRB1*09:01, and DRB1*15:02 genes. The 20-mer LP, LY6K 172-
191
-LP (KCCKIRYCNLEGPPINSSVF) was predicted to have a strong binding affinity to HLA class II molecules encoded by DRB1*09:01 and DRB1*15:02 genes and identified as a LP that [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] -lP without addition of cytokines. On day 7, cells were stained with a hla-a24/lY6K 177-186specific tetramer and anti-cD8 antibody and analyzed by flow cytometry. representative hla-a24/lY6K 177-186 -specific tetramer staining is shown (dot plots). (C) absolute number of tetramer + cD8 + cells/well. Data are the mean ± sD of triplicate assays. representative data are from 3 independent experiments with similar results achieved. spanned a known 10-mer CTL-epitope (LY6K 177-186 -A24 SP) recognized by HLA-A24-restricted CTLs (Fig. S1B; Table S1 ). Given the predicted epitope affinities for HLA class II molecules, in this study we elected to focus on these 2 LY6K-LPs.
Synthetic peptides and recombinant proteins
The human LY6K-derived SP to be presented by HLA-A24 (LY6K 177-186 -A24 SP) and the 2 candidate LPs (LY6K 119-142 -LP and LY6K 172-191 -LP) were biochemically synthesized (MBL, Nagoya, Japan; purity > 95%). A human immunodeficiency virus (HIV) peptide capable of binding to HLA-A24 (HIV-A24) was used as a SP negative control. 41 An Epstein-Barr virus nuclear antigen (EBNA)-derived LP presented by HLA-DP5 (EBNA-DP5) and a promiscuous HIV-derived LP were synthesized and used as LP negative controls. 42, 43 Peptides were dissolved in dimethylsulfoxide at 10 μg/μL. The recombinant whole LY6K and CDCA1 protein were expressed by Escherichia coli BL21 via a pET28a expression vector (Novagen). The CDCA1 protein was used as a control. Each His-tagged recombinant protein was affinity-purified and assessed by sodium-dodecyl sulfate PAGE (SDS-PAGE).
Generation of antigen-specific CD4 + T cells from healthy donors
The research protocol for collecting and using PBMCs from healthy donors was approved by the Institutional Review Board of Kumamoto University. We obtained PBMCs from 11 healthy donors with written informed consent. Genotyping of HLA-A, DRB1, DPB1, and DQB1 was performed at the HLA Laboratory ( Table S2 ). Induction of antigen-specific CD4 + T cells was performed as previously described. 20 In some instances, T cells were cloned by limiting-dilution assay and expansion in vitro, as previously described. 44 
Assessment of antigen-specific T-cell responses
The immune response of Th cells to APCs pulsed with 10 μg/ mL peptides or 50 μg/mL recombinant proteins was assessed by IFNγ ELISPOT assays (BD Biosciences) according to manufacturer's instructions and as described previously. 41, 45 In brief, the frequency of peptide-specific CD4 + T-cells producing IFNγ was analyzed per 3 × 10 4 bulk CD4 + T-cells stimulated with equal numbers of peptide-pulsed autologous PBMCs, or alternatively, 1 × 10 4 bulk CD4 + T-cells stimulated with 5 × 10 4 peptide-pulsed L-cells expressing HLA-DR or -DP molecules To determine the HLA molecules involved in antigen presentation, antigeninduced IFNγ production was blocked by adding anti-HLA-DR monoclonal antibody (mAb; L243, IgG2a, BioLegend), anti-HLA-DP mAb (B7/21, IgG3, Abcam), anti-HLA-DQ mAb (SPV-L3, IgG2a, Abcam), or the broad spectrum anti-HLA class I mAb, (W6/32, IgG2a, Abcam). All mAbs were used at a final concentration of 5 μg/mL. Cells cultured with HIV-derived peptides were used as negative control. Cells cultured with 100 ng/ mL phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich) and 500 ng/mL ionomycin (Sigma-Aldrich) were used as positive controls. All IFNγ ELISPOT assays were performed in triplicate or duplicate, and results are presented as means ± SD.
T cell receptor tetramer staining Expression of LY6K 177-186 -A24 SP specific T cell receptor (TCR) was examined via cytofluorometric analysis on a FACSCalibur (BD Biosciences) flow cytometer using a phycoerythrin (PE)-labeled tetramer of the HLA-A24 (A*24:02)/ LY6K 177-186 complex (MBL), according to the manufacturer's instructions. A PE-labeled tetramer of the HLA-A24/HIV-A24 (RYLRDQQLL) complex was used as a negative control.
In vitro cross-presentation assay Induction of LY6K 177-186 -A24 SP-reactive CTLs from an HLA-A24 + and HLA-DR15 + human donor (HD3) was performed by stimulating donor-derived lymphocytes with LY6K 177-186 -A24 SP, as previously described. 24, 46 Monocyte-derived DCs were generated from CD14 + cells by in vitro culture, as described previously. 23 Autologous immature DCs were maintained alive or fixed for 3 min in 0.1% glutaraldehyde (Sigma-Aldrich) for use as controls. DCs were pulsed with 16 μM each LY6K 177-186 -A24 SP, LY6K 172-191 -LP, or control LP for 3 h, and washed 3 times. 0.1 KE/mL OK432 was added during and after the peptide pulse to induce the maturation of DCs. LY6K 119-142 -LP, which does not include a known CTL-epitope, was used as a control LP. LY6K 177-186 -A24 SP-reactive bulk CTLs were added at a 2:1 ratio for 6 h in medium containing 10 μg/mL brefeldin A (Sigma-Aldrich). IFNγ production by LY6K 177-186 -A24 SP-specific CTLs was measured by intracellular labeling. The cells were stained with a fluorescein isothiocyanate (FITC)-labeled anti-IFNγ mAb (BioLegend) in combination with a PerCP-labeled anti-CD8 mAb (BioLegend) and a PE-labeled HLA-A24/LY6K 177-186specific tetramer.
Propagation of LY6K 177-186 -A24 SP specific CTLs by stimulation with LY6K 172-191 -LP in HNMT patients
Fresh PBMCs from 5 HNMT patients vaccinated with LY6K 177-186 -A24 SP were cultured at 1 × 10 5 /well with 10 μg/mL LY6K 172-191 -LP in a 96-well plate. Twenty IU/mL recombinant human (rh)IL-2 and 5 ng/mL rhIL-7 were added on day 0 and day 2. On day 0 (ex vivo) and day 7, the PBMCs were stained with a PE-labeled HLA-A24/LY6K 177-186 -specific tetramer and a FITC-labeled anti-CD8 mAb.
In vitro induction of LY6K-A24 177-186 SP-specific CTLs by stimulating PBMCs with LY6K 172-191 -LP To assess induction of LY6K 177-186 -A24 SP-specific CTLs from HLA-A24 + donors (HD1, HD3, and HD4) by stimulation with LY6K 172-191 -LP in vitro, 2 × 10 6 cells/well PBMCs were incubated with 7 μM LY6K 172-191 -LP in 24-well plates for 2 wk without addition of cytokines. Specifically, on day 7 post-plating, 7 μM LY6K 172-191 -LP was added to each well. On day 14 of in vitro stimulation with LY6K 172-191 -LP, the cells were harvested and stained with a PE-labeled HLA-A24/LY6K 177-186 -specific tetramer and a FITC-labeled anti-CD8 mAb.
In vivo cross-priming assay HLA-A24 (HHH) transgenic mice were kindly provided by Dr FA Lemonnier. 47 Mice were intradermally injected at the base of the tail with 100 μg LY6K 172-191 -LP solution emulsified in incomplete Freund's adjuvant (IFA), 3 times at 7-d intervals. Seven days after the third vaccination with LY6K 172-191 -LP, CD8 + T cells were isolated from inguinal lymph nodes by positive selection with magnetic microbeads (Miltenyi Biotec). The number of IFNγ producing CD8 + T cells (of 1 × 10 5 cells/well plated) in response to stimulation with LY6K 177-186 -A24 SP-pulsed bonemarrow derived DCs (2 × 10 4 cells/well) was counted by ex vivo ELISPOT assay. 20 The
synergistic effect of LY6K-LPs on induction of LY6Kspecific CTLs
To test whether LY6K-LPs could enhance induction of LY6K 177-186 -A24 SP-specific CTLs, 1 × 10 5 LY6K 119-142 -LPspecific or LY6K 172-191 -LP-specific bulk CD4 + T cells and 1 × 10 5 LY6K 177-186 -A24-specific bulk CD8 + T-cells derived from donor HD3 were cultured in 48-well plates with 2 × 10 4 autologous DCs in the presence of 10 μg/mL LY6K 177-186 -A24 SP alone, LY6K 177-186 -A24 SP + 10 μg/mL control LP, or LY6K 177-186 -A24 SP + 10 μg/mL LY6K-LP derivatives (LY6K 119-142 -LP or LY6K 172-191 -LP). After 1-wk in vitro culture with peptides, the cultured cells were stained with a HLA-A24/LY6K 177-186specific tetramer.
In another experiment, fresh PBMCs obtained from HNMT patients vaccinated with LY6K 177-186 -A24 SP were plated in a 96-well, round-bottomed culture plate (1 × 10 5 cells/well), followed by addition of 10 μg/mL LY6K 177-186 -A24 SP alone or LY6K 177-186 -A24 SP applied together with either control LP, LY6K 119-142 -LP, or LY6K 172-191 -LP (10 μg/mL) in a final volume of 200 μL AIM-V supplemented with 5% human decomplemented plasma without addition of cytokines. On day 7 of culture, cells were stained with a HLA-A24/LY6K 177-186 -specific tetramer.
Assessment of LY6K-LP-specific Th cell responses in HNMT patients
Fresh PBMCs obtained from 23 HNMT patients before and after CTL-epitope peptide-vaccination were cultured at 2 × 10 6 cells/well in 24-well plates with a mixture of 10 μg/mL each LY6K 119-142 -LP and LY6K 172-191 -LP in a final volume of 2 mL AIM-V supplemented with 5% human decomplemented plasma at 37 °C. IL-2 and IL-7 were added on days 0 and 2. After 1 wk of cell culture, the PBMCs were collected, washed, and cultured in ELISPOT plates at 1 × 10 5 cells/well with 10 μg/mL each LY6K 119-142 -LP, LY6K 172-191 -LP, or control LPs for 18 h. The number of LY6K-LPs-specific Th cells expressed as spot-forming cells/10 5 initially-plated cells was calculated after subtracting control values (background). Responses were scored as positive when both the mean number of IFNγ spots was more than 15 and the number exceeded 2-fold over background. The ELISPOT assays on patients' cells were conducted in single, duplicate, or triplicate wells with replicates constrained due to the limited number of available cells. Cells cultured with PMA and ionomycin were used as positive controls. This study was conducted in a laboratory that operates under exploratory research principles, and was performed using investigative protocols. We acknowledge the recommendations of the Minimal Information About T-cell Assay (MIATA) reporting framework for human T cell assays. 48 Statistical analysis Statistical analyses were performed by 2-tailed Student's t-test, Fisher's exact probability test, or nonparametric Mann-Whitney U test. Differences with a P value < 0.05 were considered statistically significant for all tests.
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